A product might work and yet not get registered due to stuff-ups in the trial design and thereafter, not achieving their endpoints. Regulators will only approve based on the endpoints.
That's the nature and risk of investing in biotechs and pharma companies.
The one saving grace is that the all cause ARDS Ph III trials that NVS will fund (and hopefully provide expertise in properly designing the study) be successful due to NVS input.
My position in MSB is small so am happy to leave it aside and wait patiently for the recovery.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
-0.070(2.86%) |
Mkt cap ! $3.039B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.48 | $2.35 | $8.936M | 3.711M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47497 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 68766 | 5 |
View Market Depth
| Last trade - 16.15pm 31/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |